{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015441","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.403963+00:00","generated_at":"2026-05-30T00:59:30.019570+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M","bullets":["AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.","11 blind children treated with AAV-AIPL1 all gained vision within 4+ weeks; FDA discussions initiated for similar US pathway.","AAV-GAD bridging study met safety endpoint; 18-point improvement in UPDRS Part 3 'off' score (p=0.03) at Week 26.","Three FDA Rare Pediatric Disease Designations awarded for AIPL1, BBS10, and RDH12 programs.","Cash $122.9M + $3.3M receivables; net loss $39.3M ($0.55 per share) vs $44.3M ($0.74) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015441","json":"https://secwatch.observer/filing/0001558370-24-015441.json","markdown":"https://secwatch.observer/filing/0001558370-24-015441.md","text":"https://secwatch.observer/filing/0001558370-24-015441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/0001558370-24-015441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/mgtx-20241113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:59:30.019570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}